Literature DB >> 16113347

The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice.

Brad J Spellberg1, Ashraf S Ibrahim, Valentina Avenissian, Scott G Filler, Carter L Myers, Yue Fu, John E Edwards.   

Abstract

We have previously shown that intraperitoneal vaccination with the recombinant N terminus of Als1p (rAls1p-N) modestly improves survival during murine disseminated candidiasis. We now report marked efficacy with subcutaneous rAls1p-N vaccination. Efficacy is retained in neutropenic and corticosteroid-treated mice. The rAls1p-N vaccine is a promising candidate for the prevention of invasive candidiasis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16113347      PMCID： PMC1231102          DOI： 10.1128/IAI.73.9.6191-6193.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  20 in total

Review 1.  Epidemiology of opportunistic invasive mycoses.

Authors:  B J Kullberg; A M L Oude Lashof
Journal:  Eur J Med Res       Date:  2002-05-31       Impact factor: 2.175

2.  Contribution of Candida albicans ALS1 to the pathogenesis of experimental oropharyngeal candidiasis.

Authors:  Yasuki Kamai; Mikie Kubota; Yoko Kamai; Tsunemichi Hosokawa; Takashi Fukuoka; Scott G Filler
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

3.  Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital.

Authors:  J Baran; B Muckatira; R Khatib
Journal:  Scand J Infect Dis       Date:  2001

4.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

5.  Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Candidemia in a tertiary care hospital: epidemiology and factors influencing mortality.

Authors:  H Alonso-Valle; O Acha; J D García-Palomo; C Fariñas-Alvarez; C Fernández-Mazarrasa; M C Fariñas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-22       Impact factor: 3.267

7.  Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway.

Authors:  Yue Fu; Ashraf S Ibrahim; Donald C Sheppard; Yee-Chun Chen; Samuel W French; Jim E Cutler; Scott G Filler; John E Edwards
Journal:  Mol Microbiol       Date:  2002-04       Impact factor: 3.501

8.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

9.  Major trends in the microbial etiology of nosocomial infection.

Authors:  D R Schaberg; D H Culver; R P Gaynes
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

10.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

Authors:  Peter G Pappas; John H Rex; Jeannette Lee; Richard J Hamill; Robert A Larsen; William Powderly; Carol A Kauffman; Newton Hyslop; Julie E Mangino; Stanley Chapman; Harold W Horowitz; John E Edwards; William E Dismukes
Journal:  Clin Infect Dis       Date:  2003-08-14       Impact factor: 9.079
View more
  32 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

Review 2.  Comprehensive analysis of glycosylphosphatidylinositol-anchored proteins in Candida albicans.

Authors:  Mathias L Richard; Armêl Plaine
Journal:  Eukaryot Cell       Date:  2006-12-22

3.  The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avanesian; Yue Fu; John E Edwards
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

4.  Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.

Authors:  Stephen P Saville; Anna L Lazzell; Ashok K Chaturvedi; Carlos Monteagudo; Jose L Lopez-Ribot
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

5.  Antibody titer threshold predicts anti-candidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity.

Authors:  Brad Spellberg; Ashraf S Ibrahim; Lin Lin; Valentina Avanesian; Yue Fu; Peter Lipke; Henry Otoo; Tiffany Ho; John E Edwards
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

6.  Invasive fungal infections in acute leukemia.

Authors:  Vijaya R Bhatt; George M Viola; Alessandra Ferrajoli
Journal:  Ther Adv Hematol       Date:  2011-08

7.  Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes.

Authors:  Lin Lin; Brandon Tan; Paul Pantapalangkoor; Tiffany Ho; Andrea M Hujer; Magdalena A Taracila; Robert A Bonomo; Brad Spellberg
Journal:  Vaccine       Date:  2012-11-12       Impact factor: 3.641

8.  Fungicidal monoclonal antibody C7 binds to Candida albicans Als3.

Authors:  Sonia Brena; Miren J Omaetxebarría; Natalia Elguezabal; Jonathan Cabezas; María D Moragues; José Pontón
Journal:  Infect Immun       Date:  2007-04-23       Impact factor: 3.441

9.  Functional control of the Candida albicans cell wall by catalytic protein kinase A subunit Tpk1.

Authors:  S Fanning; W Xu; C Beaurepaire; J P Suhan; A Nantel; A P Mitchell
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501

10.  Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice.

Authors:  Lin Lin; Ashraf S Ibrahim; Xin Xu; Joshua M Farber; Valentina Avanesian; Beverlie Baquir; Yue Fu; Samuel W French; John E Edwards; Brad Spellberg
Journal:  PLoS Pathog       Date:  2009-12-24       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.